Want to see ARMP full AI Analyst Report?
Total Valuation
Armata Pharmaceuticals has a market cap or net worth of $216.23M. The enterprise value is $628.10M.
Market Cap$216.23M
Enterprise Value$628.10M
Share Statistics
Armata Pharmaceuticals has 36,710,810 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding36,710,810
Owned by Insiders0.60%
Owned by Institutions7.13%
Financial Efficiency
Armata Pharmaceuticals’s return on equity (ROE) is 0.80 and return on invested capital (ROIC) is -43.07%.
Return on Equity (ROE)0.80
Return on Assets (ROA)-2.26
Return on Invested Capital (ROIC)-43.07%
Return on Capital Employed (ROCE)-0.46
Revenue Per Employee81.73K
Profits Per Employee-2.90M
Employee Count60
Asset Turnover0.06
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Armata Pharmaceuticals is ―. Armata Pharmaceuticals’s PEG ratio is -0.00159.
PE Ratio―
PS Ratio46.41
PB Ratio-1.04
Price to Fair Value-1.04
Price to FCF-8.65
Price to Operating Cash Flow-8.98
PEG Ratio-0.00159
Income Statement
In the last 12 months, Armata Pharmaceuticals had revenue of 4.90M and earned -173.80M in profits. Earnings per share was -4.80.
Revenue4.90M
Gross Profit3.37M
Operating Income-31.22M
Pretax Income-173.80M
Net Income-173.80M
EBITDA-155.68M
Earnings Per Share (EPS)-4.80
Cash Flow
In the last 12 months, operating cash flow was -23.96M and capital expenditures -506.00K, giving a free cash flow of -24.47M billion.
Operating Cash Flow-23.96M
Free Cash Flow-24.47M
Free Cash Flow per Share-0.67
Dividends & Yields
Armata Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.51
52-Week Price Change171.43%
50-Day Moving Average8.31
200-Day Moving Average7.39
Relative Strength Index (RSI)35.13
Average Volume (3m)67.60K
Important Dates
Armata Pharmaceuticals upcoming earnings date is Aug 18, 2026, TBA (Confirmed).
Last Earnings DateMay 13, 2026
Next Earnings DateAug 18, 2026
Ex-Dividend Date―
Financial Position
Armata Pharmaceuticals as a current ratio of 1.19, with Debt / Equity ratio of -119.93%
Current Ratio1.19
Quick Ratio1.19
Debt to Market Cap1.13
Net Debt to EBITDA-1.79
Interest Coverage Ratio-1.88
Taxes
In the past 12 months, Armata Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Armata Pharmaceuticals EV to EBITDA ratio is -3.26, with an EV/FCF ratio of -19.27.
EV to Sales103.37
EV to EBITDA-3.26
EV to Free Cash Flow-19.27
EV to Operating Cash Flow-19.68
Balance Sheet
Armata Pharmaceuticals has $4.75M in cash and marketable securities with $373.67M in debt, giving a net cash position of -$368.92M billion.
Cash & Marketable Securities$4.75M
Total Debt$373.67M
Net Cash-$368.92M
Net Cash Per Share-$10.05
Tangible Book Value Per Share-$6.41
Margins
Gross margin is 72.18%, with operating margin of -636.66%, and net profit margin of -3544.03%.
Gross Margin72.18%
Operating Margin-636.66%
Pretax Margin-3544.03%
Net Profit Margin-3544.03%
EBITDA Margin-3174.51%
EBIT Margin-3205.73%
Analyst Forecast
The average price target for Armata Pharmaceuticals is $17.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$17.50
Price Target Upside52.17% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast10.70%
EPS Growth Forecast-66831.90%